Roche's Avastin forestalls progression, death in brain cancer study

11/19/2012 | CNBC

Roche Holding's Avastin, in combination with radiation and chemotherapy, lowered the risk of cancer progression or death in patients with a common form of brain cancer during a Phase III trial. The drug, however, failed to significantly improve overall survival rates. Avastin is approved for treatment of several cancers including kidney and breast cancers.

View Full Article in:

CNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID